Results 51 to 60 of about 9,615 (165)

Electrocardiographic Changes Associated With Ibrutinib Exposure

open access: yes, 2020
Although ibrutinib-associated atrial and ventricular arrhythmias have been well described, there is little information about ibrutinib\u27s effects on other electrocardiographic parameters, particularly the QT interval. Using our database of 137 patients
Viganego, Federico   +12 more
core   +1 more source

Population Pharmacokinetic and Exposure‐Response Analyses of Ibrutinib Combined With Bendamustine and Rituximab in Patients With Mantle Cell Lymphoma

open access: yesCPT: Pharmacometrics & Systems Pharmacology
Efficacy and safety of ibrutinib 560 mg once daily or placebo combined with bendamustine and rituximab (BR) were assessed in patients with mantle cell lymphoma in a randomized phase 3 study (SHINE).
Per Olsson Gisleskog   +5 more
doaj   +1 more source

Second-generation inhibitors of Bruton tyrosine kinase

open access: yesJournal of Hematology & Oncology, 2016
Bruton tyrosine kinase (BTK) is a critical effector molecule for B cell development and plays a major role in lymphoma genesis. Ibrutinib is the first-generation BTK inhibitor.
Jingjing Wu   +3 more
doaj   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher   +7 more
wiley   +1 more source

Regulatory harmonization: Evolution, globalization and future directions

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Regulatory harmonization has become an increasingly important and accepted approach to streamline regulatory review processes and expedite access to safe, effective and high‐quality medicines globally. This review explores the evolution and current status of regulatory harmonization, convergence and reliance initiatives.
Orin Chisholm   +2 more
wiley   +1 more source

Ibrutinib-A double-edge sword in cancer and autoimmune disorders.

open access: yes, 2016
Targeted therapies have appeared as new treatment options for several disease types, including cancer and autoimmune disorders. Of several targets, tyrosine kinases (TKs) are among the most promising.
Håkan Mellstedt (18681301)   +5 more
core   +1 more source

Arrhythmia Patterns in Patients on Ibrutinib

open access: yesFrontiers in Cardiovascular Medicine, 2022
Introduction: Ibrutinib, a Bruton's tyrosine kinase inhibitor (TKI) used primarily in the treatment of hematologic malignancies, has been associated with increased incidence of atrial fibrillation (AF), with limited data on its association with other ...
Muhammad Fazal   +9 more
doaj   +1 more source

Population pharmacokinetics and exposure–response analysis of acalabrutinib in patients with untreated mantle cell lymphoma in the ECHO trial

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims The phase 3 ECHO trial demonstrated superior progression‐free survival (PFS) with acalabrutinib plus bendamustine‐rituximab (BR) versus placebo plus BR in treatment‐naive (TN) mantle cell lymphoma (MCL). This analysis characterizes the pharmacokinetic (PK) profile of acalabrutinib and ACP‐5862 (active metabolite) when administered with BR and ...
Damilola Olabode   +7 more
wiley   +1 more source

Trends and Future Directions in Organic Chemistry for Drug Discovery

open access: yesChemistry – A European Journal, EarlyView.
Organic synthesis is being reshaped by the convergence of catalytic innovation, automation, artificial intelligence, and emerging therapeutic modalities. Late‐stage functionalization, photoredox and electrochemical methods, biocatalysis, flow chemistry, DELs, and proximity‐based drugs are examined as components of closed‐loop discovery.
Paweł Kozyra, Maciej Masłyk
wiley   +1 more source

Dialog between mantle cell lymphoma cells and lymphoma-associated macrophages underlies ibrutinib resistance

open access: yesJournal of Advanced Research
Introduction: Patients with mantle cell lymphoma (MCL) frequently develop resistance to ibrutinib. Lymphoma-associated macrophages (LAMs) may play a causal role in this resistance but remain underexplored in current literature.
Xiaoqing Sun   +10 more
doaj   +1 more source

Home - About - Disclaimer - Privacy